Previous in vitro and in vivo studies indicate that MPs propagate a spectrum of biological activities and are involved in many different processes, such as activation of coagulation, inflammation, vascular remodeling and angiogenesis.(2-6) They bear tissue factor-dependent procoagulant activity and regulate procoagulant pathways in monocytes.(7) They also carry cytokines important for inflammation (8, 9) and participate in endothelial dysfunction by decreasing the production of nitric oxide. (4) Besides, it has been shown that endothelial MPs carry on their surface matrix metalloproteinase activity, suggesting their participation in extracellular matrix degradation, vascular remodeling and angiogenesis. (3) We previously assigned a hitherto unreported fibrinolytic function to MPs (10) and more recently, we demonstrated that they participate in a new fibrinolytic crosstalk mechanism. (11) In these in vitro studies performed with MPs derived from the human microvascular endothelial cell line, HMEC-1, we demonstrated that these endothelial MPs constitute a catalytic surface for efficient activation of plasminogen by the urokinase-type plasminogen activator (uPA) anchored to its receptor uPAR. (10) Interestingly, these MPs may also activate plasminogen bound to fibrin, extracellular matrix proteins or platelets. (11) The possibility that circulating MPs also serve as a template for plasmin formation and fibrinolytic activity in vivo and their cellular origin remains unsolved questions that are the object of the present study. We demonstrate here that blood-borne MPs are a source of fibrinolysis that is modulated in different pathological situations. This fibrinolytic activity is selectively and specifically generated by uPA on leukocyte MPs and by tPA on endothelial MPs. This novel mechanism of plasmin formation in vivo may counterbalance the effect of procoagulant MPs by contributing to lysis of fibrin clots.
Design and Methods

Isolation of microparticles from human plasma
Platelet-poor plasma was separated (1500g, 15 minutes) from blood collected into 0.119 M sodium citrate from healthy volunteers (n=36) and from patients with systemic lupus erythematosus (n=22) according to the American College of Rheumatology criteria (12) or with atherosclerotic complications (n=16) collected during a previous study (13) . Citrated plasma was also obtained by plasmapheresis from patients suffering from acute thrombotic thrombocytopenic purpura (TTP, n=10). Informed consent was obtained from all patients according to the Declaration of Helsinki.
MPs were isolated by sequential centrifugation of platelet-poor plasma, first at 12000g for 2 minutes to remove residual platelets. The platelet-free plasma was then centrifuged at 20000g for 90 minutes at 4°C. Centrifugation at 100000g, reported in some studies, was avoided to prevent concomitant sedimentation of exosomes, a different type of membrane vesicles. (14, 15) Pelleted MPs were washed twice (20000g for 90 minutes at 4°C) and re-suspended in phosphate buffer saline. In some experiments, circulating MPs were depleted in erythrocyte and platelet microparticles by magnetic immuno-separation using beads coated with CD41 and CD235a antibodies. Depletion in MPs (superior to 90%) was checked by flow cytometry (Supplemental data I). Control experiments were performed in parallel using beads coated with irrelevant antibodies.
Generation of microparticles from blood cells
To investigate which subtype of circulating MPs may support plasminogen activation activity, MPs were generated in vitro from purified blood cell types. To that aim, whole blood from healthy volunteers or patients, who had not taken anti-platelet medication for at least 2 weeks, was collected into 0.119 sodium citrated tubes. Human platelets prepared as described (16) were incubated with 1 NIH U/mL of thrombin and/or 1 µ M of ionophore A23187 (Sigma, Saint Louis, MO), and/or 10 µg/mL of collagen (Stago, Asnière, France), for 15 minutes at 37°C without stirring.
Platelets were subsequently pelleted by centrifugation first at 1500g for 15 minutes.
Residual platelets were discarded by centrifugation at 12000g for 2 minutes and microparticles were then isolated from the supernatant and washed as described above. Purity superior to 95 % was checked by flow cytometry.
Erythrocyte MPs were generated as previously described by Salzer et al. with minor modifications.(17) Erythrocytes pelleted at 200g for 10 minutes and subsequently washed in sodium chloride 0.9%, were suspended in 9 volumes of PBS containing 1 mM CaCl 2 and 5 µ M of A23187 and incubated at 37°C for 30 minutes.
Erythrocytes were subsequently separated by centrifugation at 12000g for 2 minutes, and MPs isolated and washed as described above. Purity superior to 95 % was checked by flow cytometry.
Leukocyte MPs were prepared as previously described with minor modifications.(18) Peripheral blood mononuclear cells were isolated from buffy coats by FicollTM (Lymphocytes separation medium 1077). Monocytes were isolated by CD14+ immuno-magnetic separation on MS columns (Miltenyi Biotec, Bergish Gladbach, Germany). Purity superior to 95 % was checked by flow cytometry.
Monocytes were stimulated by LPS (1µg/ml) overnight. Vesiculation was evaluated by FCM using Annexin A5-FITC/CD11b. Neutrophils were purified from buffy coats and were stimulated by N-formylmethionyl-leucyl-phenylalanine (1 µM) during 2 hours at 37ºC. Lymphocytes were purified from blood mononuclear cells and were stimulated by platelet-activating factor 500 nM/ phorbol 12-myristate 13-acetate 50 nM during 2 hours at 37ºC. MPs were isolated and washed as described above.
Generation and harvesting of microparticles from endothelial cells
Several subtypes of human endothelial cells originating from distinct vascular beds were purchased from Clonetics (Grand Island, NY) and cultured into 0.2 % gelatin coated flasks in EGM2-MV medium: renal artery endothelial cells were used at passage 8, coronary artery endothelial cells at passage 7 and both dermal human microvascular vein endothelial cells and human pulmonary artery endothelial cells at passage 6. Endothelial MPs were purified from culture medium conditioned by subconfluent endothelial cells stimulated or not with 10 ng/mL TNF-a (PeproTech Inc, Rocky Hill, NJ, USA) for 24 hours, as previously described with some modifications.(19) Culture supernatants were centrifuged at 300g for 5 min and 2500g for 10 min to remove detached cells and debris. MPs were isolated as described above, were washed twice and re-suspended in HEPES buffer.
Characterization of microparticles by flow cytometry and ELISA
MPs suspension aliquots of 10 µ L, 1/10 diluted, were labeled using fluorescein isothiocyanate (FITC)-conjugated annexin A5 (Abcys, Paris, France) or specific monoclonal antibodies. Phycoerythrin (PE)-labeled anti-CD41, FITC anti-CD31, PE anti-CD11b and PE anti-CD235a were from Beckman Coulter (Marseille, France). 
Statistical analysis
Statistical analysis was performed with KaleidaGraph software (Synergy Software, Reading, PA, USA). Significant differences were determined using non-parametric Mann-Whitney test. A p value less than 0.05 was considered significant.
Results
In vivo evidence of blood-borne fibrinolytic activity supported by microparticles: 
The fibrinolytic activity in circulating blood is borne by leukocyte-and endothelial-derived microparticles
To further explore the fibrinolytic activity of MPs, we determined the cellular origin of MPs bearing plasminogen activator activity. We first performed experiments using specific antibodies coated on magnetic beads, allowing to deplete samples in platelet and erythrocyte MPs, representing the major subpopulation of circulating MPs.
Less than 10% residual platelet MPs and erythrocyte MPs were detected in depleted samples ( Figures 3A, 3B ). The predominant subpopulations of endothelial MPs and leukocyte MPs in the depleted sample generated a significant increase in plasmin formation as compared to the non-depleted sample ( Figure 3C ). These data suggest
(1) that endothelial MPs and leukocyte MPs represent the genuine support of plasminogen activator activity and (2) that platelet or erythrocyte MPs do not contribute to the fibrinolytic activity of MPs isolated from circulating blood. Of note, platelets and platelet MPs bear active PAI-1 ( Figure 3D ). Thus, the unexpected increase in plasmin formation observed in the depleted samples was probably related to the absence of platelet MPs bearing active PAI-1.
To define which plasminogen activators are specifically borne by MPs of endothelial and leukocyte origin, we studied the fibrinolytic activity of isolated MPs were detected in lysates of endothelial MPs with a specific ELISA ( Figure 4C ). The presence of tPA was further confirmed by ELISA ( Figure 4D ) and by flow cytometry (Supplemental data II, figure S3 ), whereas uPA activity and antigen were undetectable. The molarity of active tPA borne by endothelial MPs was determined by reference to standard MPs bearing known molar amounts of tPA (Table 1) .
Leukocyte-derived microparticles. Plasminogen activator activity was also detected on leukocyte MPs of monocyte, lymphocyte and neutrophil origin ( Figure 4A ). The presence of such activity on leukocyte MPs was further confirmed by a lytic band on zymography corresponding to the position of uPA ( Figure 4B ) that was absent in the presence of antibodies to uPA (not shown). Flow cytometry (Supplemental data II, figure S3 ) and ELISA ( Figure 4D ) allowed detection of uPA and its receptor uPAR on the surface of leukocyte MPs. In a parallel experiment, tPA antigen was undetectable on leukocyte MPs (Supplemental data II, figure S3 ). The molarity of uPA borne by leukocyte MPs was calculated using reference standard MPs bearing known molar amounts of uPA (Table 2) .
Platelet-and erythrocyte-derived microparticles. Both platelet MPs and erythrocyte
MPs (up to 5.10 6 MPs per well) failed to generated plasmin ( Figure 4A ) and fibrinolytic bands ( Figure 4B ). Accordingly, depletion of erythrocyte and platelet MPs did not decrease the fibrinolytic activity of MPs isolated from plasma ( Figure 3C ). Similar negative results on plasminogen activator activity were obtained when platelet MPs were generated using different platelet agonist combinations (collagen, thrombin and A23187; not shown). Flow cytometry experiments failed also to detect uPA or tPA antigens on platelet or erythrocyte MPs (Supplemental data II, figure S3 ).
Collectively, these results indicate that active plasminogen activators expressed by endothelial cells and leukocytes, tPA and uPA respectively, are conveyed in circulating blood by endothelial and leukocyte MPs.
Discussion
Using Table 1 . tPA activity on endothelial cell-derived microparticles.
000 MPs per 50µL tPA (pM)
Renal artery endothelial cells 7.6 ± 1.0
Coronary artery endothelial cells 3.9 ± 0.1
Human microvascular endothelial cells 1.2 ± 0.2 Table 2 . uPA activity on leukocyte-derived microparticles. 
---------------------------------
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III. Preparation of reference microparticles bearing plasminogen activators
A standard curve prepared with reference microparticles (200 000 MPs per 50 µL) carrying a fixed known amount of either tPA (CHO-derived MPs) or uPA (THP1-derived MPs) was used to scale the degree of plasmin formation on respectively endothelial or leukocyte MPs.
First, reference CHO-derived MPs or THP1-derived MPs were prepared by incubation with a saturating amount of respectively tPA or uPA. The molarity of activator on these MP tPA uPA SLE1 SLE2 SLE3 SLE4 SLE5 SLE6
